{"id":19636,"date":"2023-06-01T07:29:48","date_gmt":"2023-06-01T07:29:48","guid":{"rendered":"https:\/\/clinlabint.com\/?p=19636"},"modified":"2023-06-01T07:29:48","modified_gmt":"2023-06-01T07:29:48","slug":"maxion-therapeutics-awarded-2m-innovate-uk-funding-to-develop-ion-channel-antibodies-to-treat-autoimmune-diseases","status":"publish","type":"post","link":"https:\/\/clinlabint.com\/maxion-therapeutics-awarded-2m-innovate-uk-funding-to-develop-ion-channel-antibodies-to-treat-autoimmune-diseases\/","title":{"rendered":"Maxion Therapeutics awarded \u00a32M Innovate UK funding to develop ion channel antibodies to treat autoimmune diseases"},"content":{"rendered":"<div id='av_section_1'  class='avia-section main_color avia-section-default avia-no-border-styling  avia-bg-style-scroll  avia-builder-el-0  avia-builder-el-no-sibling   container_wrap fullsize' style=' '  ><div class='container' ><main  role=\"main\" itemprop=\"mainContentOfPage\"  class='template-page content  av-content-full alpha units'><div class='post-entry post-entry-type-page post-entry-19636'><div class='entry-content-wrapper clearfix'>\n<div class=\"flex_column av_one_fifth  av-hide-on-mobile  flex_column_div av-zero-column-padding first  avia-builder-el-1  el_before_av_three_fifth  avia-builder-el-first  \" style='border-radius:0px; '><section class=\"av_textblock_section \"  itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/BlogPosting\" itemprop=\"blogPost\" ><div class='avia_textblock  '   itemprop=\"text\" ><p style=\"text-align: center\"><!--Begin ClixTrac.com Banner Code -->\r\n<a href=\"https:\/\/clixtrac.com\/goto\/?311442\" target=\"_blank\" rel=\"noopener\"><img decoding=\"async\" src=\"https:\/\/clixtrac.com\/banner\/311442.jpg\" alt=\"Bio-Rad - Preparing for a Stress-free QC Audit\" title=\"Bio-Rad - Preparing for a Stress-free QC Audit\" border=\"0\" \/><\/a>\r\n<!--End ClixTrac.com Banner Code --><\/p>\n<\/div><\/section><\/div><div class=\"flex_column av_three_fifth  flex_column_div av-zero-column-padding   avia-builder-el-3  el_after_av_one_fifth  el_before_av_one_fifth  \" style='border-radius:0px; '><section class=\"av_textblock_section \"  itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/BlogPosting\" itemprop=\"blogPost\" ><div class='avia_textblock  '   itemprop=\"text\" ><p style=\"text-align: center\"><div style=\"margin-left: auto;margin-right: auto;text-align: center;\" id=\"clinl-3578510807\"><!--Begin ClixTrac.com Banner Code -->\r\n<a href=\"https:\/\/clixtrac.com\/banner\/click.php?banner=283809\" target=\"_blank\" rel=\"noopener\">\r\n<img decoding=\"async\" src=\"https:\/\/clixtrac.com\/banner\/283809.png\" alt=\"\" title=\"\" border=\"0\"><\/a>\r\n<!--End ClixTrac.com Banner Code --><\/div><\/p>\n<\/div><\/section><br \/>\n<section class=\"av_textblock_section \"  itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/BlogPosting\" itemprop=\"blogPost\" ><div class='avia_textblock  '   itemprop=\"text\" ><header class=\"entry-content-header\"><h1 class=\"post-title entry-title\" itemprop=\"headline\">Maxion Therapeutics awarded \u00a32M Innovate UK funding to develop ion channel antibodies to treat autoimmune diseases<\/h1><span class=\"post-meta-infos\">\/ <span class=\"blog-categories minor-meta\">in <a href=\"https:\/\/clinlabint.com\/e-news\/\" rel=\"tag\">E-News<\/a>  <\/span><\/span><\/header>\n<\/div><\/section><br \/>\n<section class=\"av_textblock_section \"  itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/BlogPosting\" itemprop=\"blogPost\" ><div class='avia_textblock  '   itemprop=\"text\" ><h3>Biotechnology company Maxion Therapeutics has been awarded a \u00a32 million grant from Innovate UK, as part of its Biomedical Catalyst 2022 Round 2: Industry-led R&amp;D funding competition. The funds will support the use of Maxion\u2019s proprietary KnotBody platform <a href=\"http:\/\/www.maxiontherapeutics.com\/#technology\" target=\"_blank\" rel=\"noopener\">www.maxiontherapeutics.com\/#technology<\/a> to develop antibodies to treat autoimmune diseases (AID) with high unmet clinical need.<\/h3>\n<p><!--more--><\/p>\n<p>The funding follows Maxion\u2019s Series A financing round in February 2023 from which it raised \u00a313 million.<br \/>\nThe effective treatment of AID remains an important medical challenge and a significant area of unmet medical need. Currently, 4% of the world\u2019s population, or around 300 million people, are thought to be suffering from over 80 different autoimmune conditions. In the UK alone, 4 million people live with an autoimmune condition, with the incidence increasing by 3-9% annually.<\/p>\n<p>Antibody-based therapies have transformed the way chronic conditions like autoimmune disorders are treated, providing enhanced efficacy and safety while reducing the need for frequent administration. However, despite the success of current antibody therapies such as Humira, a significant proportion of patients do not respond well to treatment. Moreover, these therapies can lead to broad immunosuppression, increasing the risk of infections. As such, novel treatments are required that can offer broader patient coverage while minimising adverse effects.<\/p>\n<\/div><\/section><br \/>\n<div  class='avia-image-container  av-styling-    avia-builder-el-7  el_after_av_textblock  el_before_av_textblock  avia-align-center '  itemprop=\"image\" itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/ImageObject\"  ><div class='avia-image-container-inner'><div class='avia-image-overlay-wrap'><img class='avia_image' src='https:\/\/clinlabint.com\/wp-content\/uploads\/sites\/2\/2023\/06\/maxion-1030x915.jpg' alt='Maxion Therapeutics awarded \u00a32M Innovate UK funding to develop ion channel antibodies to treat autoimmune diseases' title='maxion' height=\"915\" width=\"1030\"  itemprop=\"thumbnailUrl\"  \/><\/div><\/div><\/div><br \/>\n<section class=\"av_textblock_section \"  itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/BlogPosting\" itemprop=\"blogPost\" ><div class='avia_textblock  '   itemprop=\"text\" ><h4>Innovative molecular fusion<\/h4>\n<p>Several ion channels are implicated in the pathogenesis of AID, but these critical cell surface proteins are seen as a complex target class for antibodies, with no antibody-based drugs targeting ion channels currently approved or in clinical development. At Maxion, nature has provided the answer in the form of \u201cminiproteins\u201d (knottins) that block ion channels. When knottins are fused onto the surface of antibodies, the resulting \u201cKnotBodies\u201d combine the ion channel-blocking activity of knottins with the excellent drug properties of antibodies, including long half-life in the body and the ability to further engineer their properties. This innovative molecular fusion approach serves as the foundation for Maxion&#8217;s patented KnotBody platform technology. The company\u2019s early R&amp;D efforts have yielded KnotBodies to ion channel targets involved in AID, which will be further developed as selective and long-acting first-in-class and best-in-class therapeutics using Innovate UK<\/p>\n<\/div><\/section><br \/>\n<div  class='av-social-sharing-box  avia-builder-el-9  el_after_av_textblock  avia-builder-el-last  av-social-sharing-box-minimal '><div class='av-share-box'><h5 class='av-share-link-description av-no-toc '>Share this<\/h5><ul class='av-share-box-list noLightbox'><li class='av-share-link av-social-link-facebook' ><a target=\"_blank\" aria-label=\"Share on Facebook\" href=\"https:\/\/www.facebook.com\/sharer.php?u=https:\/\/clinlabint.com\/maxion-therapeutics-awarded-2m-innovate-uk-funding-to-develop-ion-channel-antibodies-to-treat-autoimmune-diseases\/&#038;t=Maxion%20Therapeutics%20awarded%20%C2%A32M%20Innovate%20UK%20funding%20to%20develop%20ion%20channel%20antibodies%20to%20treat%20autoimmune%20diseases\" aria-hidden=\"false\" data-av_icon=\"\ue8f3\" data-av_iconfont=\"entypo-fontello\" title=\"\" data-avia-related-tooltip=\"Share on Facebook\" rel=\"noopener\"><span class='avia_hidden_link_text'>Share on Facebook<\/span><\/a><\/li><li class='av-share-link av-social-link-twitter' ><a target=\"_blank\" aria-label=\"Share on Twitter\" href=\"https:\/\/twitter.com\/share?text=Maxion%20Therapeutics%20awarded%20%C2%A32M%20Innovate%20UK%20funding%20to%20develop%20ion%20channel%20antibodies%20to%20treat%20autoimmune%20diseases&#038;url=https:\/\/clinlabint.com\/?p=19636\" aria-hidden=\"false\" data-av_icon=\"\ue8f1\" data-av_iconfont=\"entypo-fontello\" title=\"\" data-avia-related-tooltip=\"Share on Twitter\" rel=\"noopener\"><span class='avia_hidden_link_text'>Share on Twitter<\/span><\/a><\/li><li class='av-share-link av-social-link-whatsapp' ><a target=\"_blank\" aria-label=\"Share on WhatsApp\" href=\"https:\/\/api.whatsapp.com\/send?text=https:\/\/clinlabint.com\/maxion-therapeutics-awarded-2m-innovate-uk-funding-to-develop-ion-channel-antibodies-to-treat-autoimmune-diseases\/\" aria-hidden=\"false\" data-av_icon=\"\uf232\" data-av_iconfont=\"entypo-fontello\" title=\"\" data-avia-related-tooltip=\"Share on WhatsApp\" rel=\"noopener\"><span class='avia_hidden_link_text'>Share on WhatsApp<\/span><\/a><\/li><li class='av-share-link av-social-link-linkedin' ><a target=\"_blank\" aria-label=\"Share on LinkedIn\" href=\"https:\/\/linkedin.com\/shareArticle?mini=true&#038;title=Maxion%20Therapeutics%20awarded%20%C2%A32M%20Innovate%20UK%20funding%20to%20develop%20ion%20channel%20antibodies%20to%20treat%20autoimmune%20diseases&#038;url=https:\/\/clinlabint.com\/maxion-therapeutics-awarded-2m-innovate-uk-funding-to-develop-ion-channel-antibodies-to-treat-autoimmune-diseases\/\" aria-hidden=\"false\" data-av_icon=\"\ue8fc\" data-av_iconfont=\"entypo-fontello\" title=\"\" data-avia-related-tooltip=\"Share on LinkedIn\" rel=\"noopener\"><span class='avia_hidden_link_text'>Share on LinkedIn<\/span><\/a><\/li><li class='av-share-link av-social-link-mail' ><a  aria-label=\"Share by Mail\" href='mailto:?subject=Maxion%20Therapeutics%20awarded%20%C2%A32M%20Innovate%20UK%20funding%20to%20develop%20ion%20channel%20antibodies%20to%20treat%20autoimmune%20diseases&#038;body=https:\/\/clinlabint.com\/maxion-therapeutics-awarded-2m-innovate-uk-funding-to-develop-ion-channel-antibodies-to-treat-autoimmune-diseases\/' aria-hidden='false' data-av_icon='\ue805' data-av_iconfont='entypo-fontello' title='' data-avia-related-tooltip='Share by Mail'><span class='avia_hidden_link_text'>Share by Mail<\/span><\/a><\/li><\/ul><\/div><\/div><\/p><\/div><div class=\"flex_column av_one_fifth  av-hide-on-mobile  flex_column_div av-zero-column-padding   avia-builder-el-10  el_after_av_three_fifth  avia-builder-el-last  \" style='border-radius:0px; '><section class=\"av_textblock_section \"  itemscope=\"itemscope\" itemtype=\"https:\/\/schema.org\/BlogPosting\" itemprop=\"blogPost\" ><div class='avia_textblock  '   itemprop=\"text\" ><p style=\"text-align: center\"><\/p>\n<\/div><\/section><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Biotechnology company Maxion Therapeutics has been awarded a \u00a32 million grant from Innovate UK, as part of its Biomedical Catalyst 2022 Round 2: Industry-led R&amp;D funding competition. The funds will support the use of Maxion\u2019s proprietary KnotBody platform www.maxiontherapeutics.com\/#technology to develop antibodies to treat autoimmune diseases (AID) with high unmet clinical need.<\/p>\n","protected":false},"author":3,"featured_media":19637,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[35],"tags":[],"class_list":["post-19636","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-e-news"],"_links":{"self":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts\/19636","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/comments?post=19636"}],"version-history":[{"count":1,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts\/19636\/revisions"}],"predecessor-version":[{"id":19639,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/posts\/19636\/revisions\/19639"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/media\/19637"}],"wp:attachment":[{"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/media?parent=19636"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/categories?post=19636"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/clinlabint.com\/wp-json\/wp\/v2\/tags?post=19636"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}